Compare NRG Energy Inc (NRG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Tango Therapeutics Inc. — how do they compare? NRG Energy Inc trades at $100.16 (market cap $22.53B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: NRG Energy Inc is far larger — about 6× Tango Therapeutics Inc.'s market cap, and NRG Energy Inc pays a 1.77% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and Tango Therapeutics Inc. for 0 Days on average.
| NRG | TNGX | |
|---|---|---|
Market Cap | $22.53B | $3.75B |
Volume | 2,965,287 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $184.03 | $32.90 |
52-Week Low | $95.23 | $7.50 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $46.49B | $2.77B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $100.85, down 5.19% on the day amid mixed earnings results, with recent Q1 and Q2 2026 EPS misses. The stock shows neutral technical signals with bearish moving averages, while fundamentals reflect strong revenue growth to $30.71B in 2025 and a solid ROE of 26.77%, though net margins are thin at 2.56%. Recent news highlights a major 1.2 GW Texas data-center power project as a growth driver.
Outlook is cautiously optimistic given analyst consensus favoring Buy (70.37%) and a $202.90 price target, implying significant upside. Key risks include execution on large capex projects, rising debt-to-asset ratio (56.42% in 2025), and competitive pressures in utilities. The stock offers value with a low P/S of 0.66 but requires monitoring of earnings consistency and leverage trends.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
